Loading patent…
OwnerPeter Brooks, Abebe Akalu +2inventors
InventorsPeter Brooks, Abebe Akalu, Alexandra Cretu, Desiree Policarpio
Estimating the term…
The invention provides methods for identifying genes and proteins modulated by an antagonist of αvβ3 that inhibits binding of αvβ3 to an ECM component. It additionally provides methods for using the products of the identified genes, or for using the identified proteins, for inhibiting angiogenesis, tumor metastasis, and other tumor developmental processes, including cell migration, cell adhesion, cell proliferation, and tumor growth and for treating angiogenesis-dependent conditions. The present invention also relates to antagonists of αvβ3, wherein binding of these antagonists to αvβ3 results in modulation of the expression of IGFBP-4 or TSP-1, and methods of using these antagonists for inhibiting angiogenesis, tumor metastasis, and other tumor development processes as well as for treating angiogenesis-dependent conditions.
A method for identifying at least one gene or protein, wherein the expression of said gene or protein is modulated by binding of an antagonist to αvβ3, and wherein said antagonist binds to αvβ3 and inhibits binding of αvβ3 to an ECM-component, comprising the steps of:
A method for inhibiting tumor metastasis, cell adhesion, cell migration, tumor growth, cell proliferation, angiogenesis, or for treating an angiogenesis-dependent condition, comprising administering the product of a gene or administering a protein, wherein the gene or the protein is modulated by inhibiting αvβ3, wherein the gene is identified using a method for identifying at least one gene or protein that is modulated by binding of an antagonist to αvβ3, and wherein said antagonist binds to αvβ3 and inhibits binding of αvβ3 to an ECM-component, said method for identifying comprising the steps of:
An antagonist that binds to αvβ3, wherein binding of said antagonist inhibits the binding of αvβ3 to an ECM component, and wherein the binding of said antagonist to said ECM component results in modulation of IGFBP-4 or TSP-1.
A method of detecting the inhibition of tumor metastasis, cell adhesion, cell migration, tumor growth, angiogenesis, or cell proliferation by administering an antagonist that specifically binds αvβ3, comprising:
Dependencies are inferred from the claim text.